Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Paediatric Clear all
Completed Not applicable Interventional

Promoting Transactional Supports to Optimize Social Communication Outcomes for Infants and Their Families

NCT03307057
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Social Communication Growth Charts (SCGC), Parent-Implemented (P-I) Condition, Clinician-Implemented (C-I) Condition, Usual Care
Behavioral
Lead sponsor
Emory University
Other
Eligibility
6 Months to 6 Months
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

NCT03245151
View directory record Official record
Conditions
Recurrent and Refractory Solid Tumors
Interventions
Lenvatinib, Everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

NCT01818492
View directory record Official record
Conditions
Primary Haemophagocytic Lymphohistiocytosis
Interventions
NI-0501
Biological
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Up to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Aurora, Colorado • Wilmington, Delaware • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 12, 2026, 1:05 AM EDT
Terminated Not applicable Interventional

Metabolic Response to Infliximab in Pediatric Ulcerative Colitis

NCT00586807
View directory record Official record
Conditions
Ulcerative Colitis, Protein Metabolism, Energy Expenditure
Interventions
Stable amino acid isotopes
Other
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Sep 12, 2026, 1:05 AM EDT
Not yet recruiting Phase 1 Interventional

Magnesium Sulfate in Pediatric Burn Dressing Changes

NCT07126795
View directory record Official record
Conditions
Pediatric Burns
Interventions
magnesium sulfate, Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Not applicable Interventional Results available

Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE)

NCT02798354
View directory record Official record
Conditions
Diagnostic Errors
Interventions
Quality Improvement Collaborative
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
26 Years and older
Enrollment
13,853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 12, 2026, 1:05 AM EDT
Terminated Not applicable Interventional

Effectiveness Trial of Mobile ESI for Toddlers With Autism Identified by Early Screening in Primary Care

NCT05456139
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Treatment as Usual, Early Social Interaction Mobile Coaching (ESI-MC)
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
15 Months to 20 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Tallahassee, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 12, 2026, 1:05 AM EDT
Not listed No phase listed Observational

Pediatric Acute Gastrointestinal Bleeding Registry

NCT03090945
View directory record Official record
Conditions
Upper Gastrointestinal Bleeding, Gastro Intestinal Bleeding
Interventions
This is an obsevational cohort study
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT02555215
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

Phase 3/Safety & Efficacy of Esomeprazole in Infants

NCT00468559
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Month to 11 Months
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changing Pediatric Office Systems Nationally to Address Parental Tobacco Use

NCT01882348
View directory record Official record
Conditions
Tobacco Dependence
Interventions
CEASE Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3,888 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

High Dose Vitamin D for Sickle Cell Disease

NCT01331148
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Vitamin D, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 12, 2026, 1:05 AM EDT
Recruiting No phase listed Observational

Cranial Ultrasound for Point of Care Intracranial Pathology Detection in Pediatrics

NCT06697808
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 18 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Not applicable Interventional Results available

Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics

NCT03966911
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus
Interventions
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Escondido, California • Santa Barbara, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 12, 2026, 1:05 AM EDT
Recruiting Phase 4 Interventional

Safety of Short-course of NSAIDs in Pediatric Patients With CKD

NCT06860711
View directory record Official record
Conditions
Chronic Kidney Disease, Pediatric Urology
Interventions
NSAIDs, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Months to 25 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 12, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

NCT02187809
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Clobazam
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
1 Year to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

NCT02124772
View directory record Official record
Conditions
Cancer
Interventions
Trametinib, Dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age

NCT01159262
View directory record Official record
Conditions
Sedation
Interventions
Midazolam, Fentanyl/Morphine, Dexmedetomidine
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Weeks to 44 Weeks
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
17
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Early Phase 1 Interventional Results available

Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia

NCT04963764
View directory record Official record
Conditions
Pneumonia, Pediatric Respiratory Diseases, Antibiotic Use, Community-acquired Pneumonia
Interventions
Amoxicillin, Placebo
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 71 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 12, 2026, 1:05 AM EDT
Completed Phase 4 Interventional

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

NCT00400608
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR HFA, ADVAIR DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Huntington Beach, California • Long Beach, California • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 12, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Results available

Gemcabene for the Treatment of Pediatric NAFLD

NCT03436420
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Gemcabene
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Sep 12, 2026, 1:05 AM EDT
Withdrawn Not applicable Interventional

Relaxation Breathing Training for Children

NCT03271086
View directory record Official record
Conditions
Stress Disorder, Biofeedback
Interventions
The StressEraser, Breathe2Relax, Reminder text messages
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
6 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 12, 2026, 1:05 AM EDT
Terminated Not applicable Interventional

Cardiac Arrhythmias and Dysfunction in the Pediatric Burn Patient

NCT03085420
View directory record Official record
Conditions
Cardiac Dysfunction
Interventions
Echocardiogram
Diagnostic Test
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
Up to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 12, 2026, 1:05 AM EDT